Pre-Mixed Drug for Hyponatremia Okayed

Share this content:

Vaprisol (conivaptan hydrochloride injection) Premixed in 5% Dextrose, a new formulation of Vaprisol developed by Astellas Pharma US, Inc., has been approved for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients.


The ampule formulation of Vaprisol, an arginine vasopressin receptor antagonist, was originally cleared by the FDA for the treatment of euvolemic hyponatremia in December 2005 and hypervolemic hyponatremia in February 2007.


“This [new] ready-to-use product will be useful for hospitals and emergency rooms,” said Joseph Verbalis, MD, professor of medicine and physiology at Georgetown University in Washington, D.C.

You must be a registered member of Renal and Urology News to post a comment.